📊 FLGT Key Takeaways
Is FLGT a Good Investment? Thesis Analysis
Fulgent Genetics demonstrates a fundamental disconnect between revenue growth and profitability, with negative operating income of $91.1M on $322.7M revenue indicating severe operational challenges. The company is burning substantial cash with operating cash flow of -$101.6M and free cash flow of -$124.2M, which is unsustainable despite maintaining a strong liquidity position. The deteriorating margins (40.6% gross, -28.2% operating) suggest structural cost issues that cannot be addressed through scaling.
Why Buy FLGT? Key Strengths
- Revenue growth of 13.8% YoY demonstrates continued demand for genetic testing services
- Exceptional liquidity position with current ratio of 6.48x and $50.2M cash provides runway for operations
- Zero long-term debt and minimal total liabilities ($106.8M) limits financial distress risk in near term
FLGT Investment Risks to Consider
- Operating cash flow of -$101.6M indicates the company is not generating cash from core operations despite revenue growth
- Negative free cash flow of -$124.2M (-38.5% FCF margin) is unsustainable and will deplete cash reserves within months
- Operating margin of -28.2% and net margin of -18.8% show the business model is fundamentally unprofitable at current scale
- 12 Form 4 insider filings in last 90 days may indicate insider selling amid operational distress
- Cost structure appears misaligned with revenue generation, suggesting operational efficiency crisis
Key Metrics to Watch
- Operating cash flow trend - must turn positive to validate business viability
- Gross margin stability - erosion would indicate competitive pressure on pricing
- Operating expense reduction timeline - critical to achieving profitability
- Cash burn rate and runway - at current pace will deplete reserves within 6 months
- Operating leverage improvement - need to see gross profit growth exceed expense growth
FLGT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.48x current ratio provides a solid financial cushion.
FLGT Profitability Ratios
FLGT vs Healthcare Sector
How Fulgent Genetics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FLGT Overvalued or Undervalued?
Based on fundamental analysis, Fulgent Genetics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FLGT Balance Sheet & Liquidity
FLGT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Fulgent Genetics, Inc.'s revenue has declined by 67% over the 5-year period, indicating business contraction. The most recent EPS of $-5.63 indicates the company is currently unprofitable.
FLGT Growth Metrics (YoY)
FLGT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $71.7M | -$6.6M | $-0.21 |
| Q2 2025 | $71.0M | -$8.7M | $-0.29 |
| Q1 2025 | $64.5M | -$11.5M | $-0.37 |
| Q3 2024 | $71.7M | -$13.1M | $-0.44 |
| Q2 2024 | $67.9M | -$8.7M | $-0.29 |
| Q1 2024 | $64.5M | -$13.5M | $-0.45 |
| Q3 2023 | $84.7M | $1.7M | $0.06 |
| Q2 2023 | $67.9M | -$11.2M | $0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FLGT Capital Allocation
FLGT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Fulgent Genetics, Inc. (CIK: 0001674930)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FLGT
What is the AI rating for FLGT?
Fulgent Genetics, Inc. (FLGT) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FLGT's key strengths?
Claude: Revenue growth of 13.8% YoY demonstrates continued demand for genetic testing services. Exceptional liquidity position with current ratio of 6.48x and $50.2M cash provides runway for operations.
What are the risks of investing in FLGT?
Claude: Operating cash flow of -$101.6M indicates the company is not generating cash from core operations despite revenue growth. Negative free cash flow of -$124.2M (-38.5% FCF margin) is unsustainable and will deplete cash reserves within months.
What is FLGT's revenue and growth?
Fulgent Genetics, Inc. reported revenue of $322.7M.
Does FLGT pay dividends?
Fulgent Genetics, Inc. does not currently pay dividends.
Where can I find FLGT SEC filings?
Official SEC filings for Fulgent Genetics, Inc. (CIK: 0001674930) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FLGT's EPS?
Fulgent Genetics, Inc. has a diluted EPS of $-0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FLGT a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Fulgent Genetics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FLGT stock overvalued or undervalued?
Valuation metrics for FLGT: ROE of -5.4% (sector avg: 15%), net margin of -18.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FLGT stock in 2026?
Our dual AI analysis gives Fulgent Genetics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FLGT's free cash flow?
Fulgent Genetics, Inc.'s operating cash flow is $-101.6M, with capital expenditures of $22.6M. FCF margin is -38.5%.
How does FLGT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -18.8% (avg: 12%), ROE -5.4% (avg: 15%), current ratio 6.48 (avg: 2).